{"id":2758,"date":"2026-09-30T13:11:18","date_gmt":"2026-09-30T08:11:18","guid":{"rendered":"https:\/\/journal.nncf.kz\/?p=2758"},"modified":"2026-10-10T13:14:07","modified_gmt":"2026-10-10T08:14:07","slug":"cxcl10-ip-10-%d0%b8-il-18-%d0%ba%d0%b0%d0%ba-%d0%b8%d0%bc%d0%bc%d1%83%d0%bd%d0%be%d0%bb%d0%be%d0%b3%d0%b8%d1%87%d0%b5%d1%81%d0%ba%d0%b8%d0%b5-%d0%b1%d0%b8%d0%be%d0%bc%d0%b0%d1%80%d0%ba%d0%b5%d1%80","status":"publish","type":"post","link":"https:\/\/journal.nncf.kz\/en\/cxcl10-ip-10-%d0%b8-il-18-%d0%ba%d0%b0%d0%ba-%d0%b8%d0%bc%d0%bc%d1%83%d0%bd%d0%be%d0%bb%d0%be%d0%b3%d0%b8%d1%87%d0%b5%d1%81%d0%ba%d0%b8%d0%b5-%d0%b1%d0%b8%d0%be%d0%bc%d0%b0%d1%80%d0%ba%d0%b5%d1%80\/","title":{"rendered":"CXCL10\/IP-10 \u0418 IL-18 \u041a\u0410\u041a \u0418\u041c\u041c\u0423\u041d\u041e\u041b\u041e\u0413\u0418\u0427\u0415\u0421\u041a\u0418\u0415 \u0411\u0418\u041e\u041c\u0410\u0420\u041a\u0415\u0420\u042b \u0423 \u041f\u0410\u0426\u0418\u0415\u041d\u0422\u041e\u0412 \u0421 \u0412\u041f\u0415\u0420\u0412\u042b\u0415 \u0412\u042b\u042f\u0412\u041b\u0415\u041d\u041d\u042b\u041c \u0422\u0423\u0411\u0415\u0420\u041a\u0423\u041b\u0415\u0417\u041e\u041c \u041b\u0415\u0413\u041a\u0418\u0425: \u041e\u0411\u0417\u041e\u0420 \u041b\u0418\u0422\u0415\u0420\u0410\u0422\u0423\u0420\u042b"},"content":{"rendered":"

Received by the Editorial Office: September 0<\/em>2<\/em>, 2026 <\/em><\/p>\n

Accepted for publication: September <\/em>28<\/em>, 2026 <\/em><\/p>\n

Published online: September 30, 2026<\/em><\/p>\n

UDC: 616.24-002.5-08-097<\/p>\n

DOI: 10.26212\/2227-1937.2026.92.49.010<\/a><\/p>\n

 <\/p>\n

Article type:<\/em><\/strong> Narrative literature review<\/em><\/p>\n

 <\/p>\n

CXCL10\/IP-10 AND IL-18 AS IMMUNOLOGICAL BIOMARKERS IN PATIENTS WITH NEWLY DIAGNOSED PULMONARY TUBERCULOSIS: A LITERATURE REVIEW<\/p>\n

 <\/p>\n

Yermekbayeva K.Zh.<\/strong>1<\/sup><\/strong>,<\/strong> Dilmagambetov D.S.<\/strong>1<\/sup><\/strong>, <\/strong>Almagambetova A.S.<\/strong>1<\/sup><\/strong>, <\/strong><\/p>\n

Zimina V.N.2<\/sup>, Adilova A.U.3<\/sup>, Tanzharykova G. N.<\/strong>1<\/sup><\/strong><\/p>\n

1<\/sup><\/em>NJSC \u201cWest Kazakhstan Marat Ospanov Medical University\u201d, Aktobe, Kazakhstan<\/em><\/p>\n

2<\/sup><\/em>FSBEI of HE \u201cKemerovo State Medical University\u201d of the Ministry of Health of the Russian Federation, Kemerovo, Russia<\/em><\/p>\n

3<\/sup><\/em>SCE on REM \u201cAktobe Regional Phthisiopulmonology Center\u201d, Aktobe, Kazakhstan<\/em><\/p>\n

 <\/p>\n

Introduction.<\/strong> Tuberculosis remains a major global public health problem, with pulmonary tuberculosis representing the principal transmissible form of the disease. Host-response biomarkers may complement microbiological testing by providing information on disease activity and treatment-related immune changes. CXCL10\/IP-10 and interleukin-18 participate in interferon-mediated and inflammasome-associated immune responses, but their clinical roles remain incompletely defined.<\/p>\n

Objective.<\/strong> To summarize evidence on the diagnostic and prognostic significance of CXCL10\/IP-10 and interleukin-18 and their potential value for treatment monitoring in adults with newly diagnosed pulmonary tuberculosis.<\/p>\n

Materials and Methods.<\/strong> A structured narrative review was conducted using English-language publications indexed in Scopus and the Web of Science Core Collection from January 2016 to August 2026. A total of 373 records were identified, of which 129 duplicates were removed. Following relevance assessment and full-text evaluation, 37 publications were included: 33 original clinical studies and four systematic reviews\/meta-analyses.<\/p>\n

Results.<\/strong> Circulating CXCL10\/IP-10 was commonly elevated in active pulmonary tuberculosis and was associated in several cohorts with mycobacterial burden, radiological extent, and systemic inflammation. Diagnostic performance varied according to comparator group, HIV status, biological specimen, assay method, and antigen stimulation. Pooled sensitivity\/specificity for differentiating active from latent tuberculosis infection were 72%\/78% for unstimulated IP-10 and 82%\/85% after stimulation with Mycobacterium tuberculosis<\/em>-specific antigens. During effective treatment, circulating CXCL10\/IP-10 generally declined, particularly during the first one to two months, and contributed to multivariable models of microbiological conversion and unfavorable outcomes. Evidence for interleukin-18 was more limited and heterogeneous. Elevated IL-18 was reported in active or more extensive disease; decreases during treatment were observed in selected longitudinal studies, and higher baseline IL-18 was associated with delayed sputum-smear conversion.<\/p>\n

Discussion.<\/strong> The overall evidence base is more consistent for CXCL10\/IP-10 than for IL-18. CXCL10\/IP-10 appears most promising as an adjunctive marker of disease activity and treatment-related change, whereas IL-18 may have greater value as part of multibiomarker inflammatory panels. Substantial heterogeneity in specimens, assay methods, comparator groups, and comorbid conditions currently limits the establishment of universal diagnostic or prognostic thresholds.<\/p>\n

Conclusion.<\/strong> Current evidence supports further evaluation of CXCL10\/IP-10 as an adjunctive marker of pulmonary tuberculosis activity and treatment-related change. IL-18 may provide complementary information in selected inflammatory or multibiomarker models but requires additional validation. Standardized prospective studies are needed to determine the incremental clinical value of combined CXCL10\/IP-10 and IL-18 measurement for treatment monitoring and outcome prediction.<\/p>\n

Keywords:<\/strong> pulmonary tuberculosis, CXCL10\/IP-10, interleukin-18, immunological biomarkers, treatment monitoring, prognosis.<\/p>\n\n